Fawad Ali Shah | Neuropharmacology |

Posted on by Neuroscientists

Dr. Fawad Ali Shah | Neuropharmacology | Best Researcher Award

Dr. Fawad Ali Shah,  Prince Sattam bin Abdulaziz University, Saudi Arabia.

Dr. Fawad Ali Shah is an accomplished neuroscientist and pharmacologist whose academic journey began with a Pharm-D from the University of Malakand, Pakistan, and culminated in a Ph.D. in Neuroscience and Pharmacology from Gyeongsang National University, South Korea. With a strong foundation in neuroprotective pharmacology, his doctoral and postdoctoral research has focused on natural therapeutic agents for cerebral ischemia and brain injury. Professionally, he has held key academic roles in Pakistan, South Korea, Canada, and Saudi Arabia, currently serving as an Associate Professor at Prince Sattam Bin Abdulaziz University.

Profile

Scopus

🎓 Early Academic Pursuits

Dr. Fawad Ali Shah embarked on his academic journey with a profound interest in pharmaceutical sciences and neuroscience. He earned his Doctor of Pharmacy (Pharm-D) degree from the University of Malakand, Khyber Pakhtunkhwa, Pakistan, in 2010 with a First Division and a solid 70.88% score. His thesis, which explored ischemic and reperfusion injuries and their clinical implications, laid a strong foundation for his lifelong dedication to the neuropharmacological sciences. Driven by a deeper quest for knowledge, he pursued his Ph.D. at the esteemed Gyeongsang National University (GNU) in South Korea, where he specialized in neuroscience and pharmacology. Graduating with an A+ average in 2017, his doctoral research focused on investigating the neuroprotective effects of natural drug substances in models of cerebral ischemic injury. This blend of clinical insight and experimental pharmacology set the stage for his career in neuropharmacological research.

🧠 Professional Endeavors in Neuroscience

After earning his doctorate, Dr. Shah’s professional journey took a dynamic course across academia and clinical research institutions. He began as a Research Scholar and Lab Coordinator in the Neurobiology and Brain Histology Lab at GNU, deepening his technical expertise in neurohistology and preclinical pharmacology. Following this, he was appointed as Assistant Professor and then promoted to Associate Professor at Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad. His academic ascent continued with two prestigious postdoctoral positions: a lab-based postdoctoral fellowship at Robarts Research Institute, University of Western Ontario, Canada, and another at the University of Toronto. In 2022, he joined Prince Sattam Bin Abdulaziz University, Saudi Arabia, as an Associate Professor in the Department of Pharmacology and Toxicology. His teaching and mentorship roles have nurtured aspiring pharmacists and neuroscientists alike, while his hands-on work as a former Associate Pharmacist at GlaxoSmithKline (GSK) and Biogenics added vital industry experience to his academic pursuits.

🔬 Research Focus and Scientific Contributions

Dr. Shah’s research is anchored in the exploration of neuroprotective strategies, particularly involving natural drug substances in mitigating cerebral ischemia and related neuronal injuries. His scientific endeavors are characterized by a translational approach—bridging preclinical findings with potential therapeutic implications. Through a series of methodical investigations during his Ph.D. and postdoctoral tenures, he contributed to the understanding of ischemic brain injury mechanisms, drug-induced neuroprotection, and histopathological changes associated with brain trauma. He has significantly advanced the neuropharmacology discipline by contributing original research that addresses real-world health challenges, such as stroke and neurodegenerative conditions. His collaborations in Canadian research institutions have further enriched his methodological expertise and international research exposure.

📚 Teaching Excellence and Academic Impact

As a seasoned academic, Dr. Shah has been instrumental in delivering rigorous pharmacology and toxicology curricula to undergraduate and graduate pharmacy students. His dual role as a researcher and educator has empowered students with both theoretical understanding and laboratory proficiency. His mentorship extends beyond the classroom, guiding research projects and helping students build critical thinking in experimental neuroscience. His affiliation with academic institutions in Pakistan, South Korea, and Saudi Arabia demonstrates his global academic influence and his ability to adapt to diverse educational environments. His role in curriculum development and departmental leadership has contributed to the overall elevation of academic standards wherever he has served.

🏅 Recognition and Accolades

Dr. Fawad Ali Shah is an HEC (Higher Education Commission) Approved Supervisor, a recognition that attests to his academic merit and capability to guide M.Phil. and Ph.D. research. His scholarly distinction, demonstrated by first-class academic performance and international postdoctoral achievements, has earned him esteem in both academic and research circles. His involvement with reputed institutions like the University of Toronto and Robarts Research Institute has positioned him among globally recognized neuroscientists contributing to pharmacological innovation and brain research.

🌍 Global Reach and Influence

Dr. Shah’s academic and research footprints span several continents, including Asia, North America, and the Middle East. His international collaborations and transdisciplinary research have helped forge global scientific alliances. Through participation in international conferences, seminars, and research initiatives, he has disseminated key findings in neuropharmacology and inspired academic exchanges. His commitment to ethical and impactful research, along with his cross-border academic contributions, highlights his role as a globally engaged scholar advancing neuroscience for public health benefits.

🔮 Vision, Legacy, and Future Contributions

Looking ahead, Dr. Shah envisions expanding the therapeutic potential of natural compounds in managing neurodegenerative and cerebrovascular diseases. He aspires to establish advanced neuropharmacology labs in collaboration with global research centers to facilitate translational research and innovative drug discovery. His legacy lies in nurturing a new generation of neuroscientists, fostering research with clinical relevance, and strengthening the bridge between pharmaceutical education and neurological care. With a growing portfolio of impactful publications and international engagements, Dr. Shah is poised to remain a leading voice in neurotherapeutics and pharmacological innovation.

Publication

  1. Title: Carvacrol attenuated haloperidol-induced Parkinson’s disease via TNF/NFκβ-NLRP3-mediated pyroptosis
    Author(s): Not listed
    Year: 2025
    Journal: Laboratory Animal Research

 

  1. Title: In Silico molecular docking and molecular dynamic simulation of transferrin coated Phenytoin loaded SLNs with molecular targets of epilepsy
    Author(s): Not listed
    Year: 2025
    Journal: PLOS ONE

 

  1. Title: Carvacrol attenuated myocardial infarction through NLRP3-mediated pyroptosis and mTOR/Nrf2/PPARγ-dependent autophagic signaling
    Author(s): Not listed
    Year: 2025
    Journal: Toxicology and Applied Pharmacology

 

  1. Title: Retraction notice to “Quercetin attenuated ischemic stroke induced neurodegeneration by modulating glutamatergic and synaptic signaling pathways”
    Author(s): Not listed
    Year: 2024
    Journal: Heliyon

 

  1. Title: Ghrelin’s modulation of growth hormone secretagogue receptors in primary glioblastoma and meningioma: A comprehensive in-vitro study
    Author(s): Not listed
    Year: 2025
    Journal: Biochemical and Biophysical Research Communications

 

  1. Title: Corrigendum to “pH-Sensitive Tacrolimus loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease”
    Author(s): Not listed
    Year: 2024
    Journal: European Journal of Pharmaceutics and Biopharmaceutics

 

  1. Title: Punicalagin improves inflammation and oxidative stress in rat model of pelvic inflammatory disease
    Author(s): Not listed
    Year: 2025
    Journal: Natural Product Research

 

  1. Title: Core-shell tablets designed for modified and sequential release of ibuprofen and rabeprazole
    Author(s): Not listed
    Year: 2024
    Journal: International Journal of Pharmaceutics

 

  1. Title: Effect of Bacillus clausii in attenuating symptoms of DSS-induced ulcerative colitis by modulating NFkB pathway and oxidative stress in mice
    Author(s): Not listed
    Year: 2024
    Journal: Clinical and Experimental Pharmacology and Physiology

 

  1. Title: Paroxetine Loaded Nanostructured Lipid Carriers Based In-situ Gel for Brain Delivery via Nasal Route for Enhanced Anti-Depressant Effect: In Vitro Prospect and In Vivo Efficacy
    Author(s): Not listed
    Year: 2024
    Journal: AAPS PharmSciTech

 

🧾 Conclusion

Dr. Fawad Ali Shah stands out as a dedicated researcher, educator, and global academic contributor in the fields of neuroscience and pharmacology. His blend of international experience, pioneering research on natural neuroprotective agents, and commitment to academic excellence underscores his significant role in the advancement of neurotherapeutics. As he continues to inspire future scientists and lead innovative research, his impact will resonate across both the scientific and clinical communities, shaping the future of neurological health and pharmaceutical sciences.

Ling-Yan Su | Molecular Neuroscience | Best Researcher Award

Posted on by Neuroscientists

Dr. Ling-Yan Su | Molecular Neuroscience | Best Researcher Award

Dr. Ling-Yan Su, Yunnan Agricultural University, China.

Professor Ling-Yan Su is a leading figure in the field of food science and plant physiology, currently serving at the College of Food Science and Technology, Yunnan Agricultural University. With a solid academic foundation from Yunnan University and the Chinese Academy of Sciences, she has built a dynamic career that bridges molecular biology and applied agricultural research. Her pioneering work on melatonin-based pre-harvest treatments has significantly advanced our understanding of natural preservation techniques, especially in prolonging the post-harvest life and quality of fruits like Myrica rubra. Her research focuses on enhancing antioxidant systems, inhibiting spoilage, and activating plant defense pathways through sustainable, low-toxicity treatments.

Profile

Google Scholar

 

🎓 Early Academic Pursuits

Ling-Yan Su’s journey in the biological sciences began with a Bachelor of Science degree from the School of Life Science at Yunnan University (2007–2011). Demonstrating academic curiosity and determination early on, she expanded her horizons through a year-long visiting student program (2010–2011) at the prestigious Kunming Institute of Zoology, affiliated with the Chinese Academy of Sciences. This experience laid the foundation for her doctoral research, which she pursued at the same institute from 2011 to 2017, where she rigorously explored complex biological systems, further solidifying her passion for food science and plant physiology.

🧪 Professional Endeavors in Science

Professor Su’s professional career has been marked by consistent growth across esteemed academic institutions. Following her Ph.D., she joined the Kunming Institute of Zoology as a research assistant, rapidly advancing to the role of associate professor. In 2022, she transitioned to the College of Food Science and Technology at Yunnan Agricultural University, initially as an associate professor before her promotion to full professor within the same year. Her academic trajectory reflects a blend of deep research engagement and an evolving role in shaping food science education and innovation in China.

🌿 Contributions and Research Focus

Professor Su’s groundbreaking work lies at the intersection of plant physiology, post-harvest fruit biology, and food preservation technology. She has made significant contributions to understanding how melatonin, a naturally occurring compound, can be leveraged to extend the post-harvest shelf life of Myrica rubra (Chinese bayberry). Her studies demonstrate that melatonin pre-harvest treatments reduce oxidative stress markers, inhibit microbial decay, and activate the phenylpropanoid pathway, resulting in elevated antioxidant activity. This line of research not only reveals novel mechanisms of fruit preservation but also opens sustainable avenues in post-harvest biology and food safety.

🏅 Accolades and Recognition

While formal awards are not listed, Professor Su’s rapid academic promotions and appointments at prestigious research institutes such as the Chinese Academy of Sciences and Yunnan Agricultural University underscore her recognition within the scientific community. Her work is contributing to a growing body of literature on sustainable food science innovations, earning her esteem among peers and collaborators in the agricultural biotechnology field.

🌱 Impact and Influence

Professor Su’s innovative application of melatonin in fruit preservation has substantial implications for food technology and agricultural practices. Her research directly addresses global concerns such as food spoilage, post-harvest losses, and chemical-free preservation methods. By enhancing natural antioxidant defenses and inhibiting spoilage at a molecular level, her work supports both farmers and consumers in accessing healthier and longer-lasting produce, especially within the context of environmentally conscious food systems.

🔬 Legacy in Food Science

The legacy Professor Su is building centers around translating scientific inquiry into practical solutions for real-world agricultural challenges. Her research is charting a course for future studies in the bio-preservation of fruits and vegetables using natural treatments. As she continues to mentor students and collaborate across disciplines, her influence is extending into the next generation of food scientists and researchers focused on plant biochemistry, post-harvest technology, and sustainable agricultural innovation.

🚀 Future Contributions and Vision

Looking ahead, Professor Ling-Yan Su is poised to further explore how endogenous compounds like melatonin can be applied across various fruits and food crops. Her vision includes broadening the scope of natural food preservation strategies and delving deeper into molecular pathways that regulate plant defense responses. As a respected academic and scientist, her future contributions are expected to shape healthier food systems and deepen scientific understanding of plant–microbe–compound interactions.

Publication

  • Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)
    Authors: DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, …
    Year: 2021

 

  • Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model
    Authors: R Luo, LY Su, G Li, J Yang, Q Liu, LX Yang, DF Zhang, H Zhou, M Xu, …
    Year: 2020

 

  • Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5-mediated autophagy and SNCA/α-synuclein aggregation
    Authors: LY Su, H Li, L Lv, YM Feng, GD Li, R Luo, HJ Zhou, XG Lei, L Ma, JL Li, …
    Year: 2015

 

  • Decreased mitochondrial DNA copy number in the hippocampus and peripheral blood during opiate addiction is mediated by autophagy and can be salvaged by melatonin
    Authors: YM Feng, YF Jia, LY Su, D Wang, L Lv, L Xu, YG Yao
    Year: 2013

 

  • Association of the LRRK2 genetic polymorphisms with leprosy in Han Chinese from Southwest China
    Authors: D Wang, L Xu, L Lv, LY Su, Y Fan, DF Zhang, R Bi, D Yu, W Zhang, XA Li, …
    Year: 2015

 

  • Atg5- and Atg7-dependent autophagy in dopaminergic neurons regulates cellular and behavioral responses to morphine
    Authors: LY Su, R Luo, Q Liu, JR Su, LX Yang, YQ Ding, L Xu, YG Yao
    Year: 2017

 

  • Positive selection rather than relaxation of functional constraint drives the evolution of vision during chicken domestication
    Authors: MS Wang, R Zhang, LY Su, Y Li, MS Peng, HQ Liu, L Zeng, DM Irwin, …
    Year: 2016

 

  • Melatonin alleviates morphine analgesic tolerance in mice by decreasing NLRP3 inflammasome activation
    Authors: Q Liu, LY Su, C Sun, L Jiao, Y Miao, M Xu, R Luo, X Zuo, R Zhou, P Zheng, …
    Year: 2020

 

  • Out of Southern East Asia of the brown rat revealed by large-scale genome sequencing
    Authors: L Zeng, C Ming, Y Li, LY Su, YH Su, NO Otecko, A Dalecky, S Donnellan, …
    Year: 2018

 

  • Moringa oleifera Lam. leaves as new raw food material: A review of its nutritional composition, functional properties, and comprehensive application
    Authors: M Yang, L Tao, XR Kang, ZL Wang, LY Su, LF Li, F Gu, CC Zhao, J Sheng, …
    Year: 2023

 

✅ Conclusion

Professor Su’s academic journey and research contributions exemplify scientific excellence rooted in sustainability and innovation. Her work not only provides practical solutions to post-harvest challenges but also contributes to broader efforts in reducing food waste and promoting natural preservation methods. As she continues to mentor young researchers and expand her studies, Professor Su is well-positioned to leave a lasting impact on food science and agricultural biotechnology. Her career reflects a thoughtful integration of research, application, and forward-looking vision in the quest for healthier and more resilient food systems.

Jørgen Slots | Clinical Neuroscience |

Posted on by Neuroscientists

Prof. Dr. Jørgen Slots | Clinical Neuroscience | Best Researcher Award

Prof. Dr. Jørgen Slots, University of Southern California,  United States.

Dr. Jørgen Slots is an internationally recognized scholar in periodontology and oral microbiology, with a rich academic and professional background rooted in Denmark, the United States, and Sweden. After completing multiple advanced degrees—including a D.D.S., Ph.D., D.M.D., and M.B.A.—he held tenured and leadership roles at esteemed institutions such as the Royal Dental College, SUNYAB, and the University of Göteborg. His research focused on microbial causes of periodontal disease, bridging the gap between laboratory science and clinical treatment. Throughout his career, he has been a pioneer in integrating microbiology into dental education and has significantly influenced both teaching and clinical standards globally. His work continues to inform practices in oral health and inspire the next generation of researchers and clinicians.

Profile

Google Scholar

🎓 Early Academic Pursuits

Born in 1944 in Vejle, Denmark, Dr. Jørgen Slots embarked on a lifelong journey in dentistry and biomedical science that began at the prestigious Royal Dental College in Copenhagen. He earned his D.D.S. in 1969 and continued to delve deeper into academic excellence with an M.S. (Lic. Odont.) in 1974. His passion for periodontology led him to complete postgraduate education in this specialty by 1976, setting the stage for a research-intensive career. Not stopping there, he pursued advanced studies in microbiology at the Forsyth Dental Center in Boston, Massachusetts, where he earned a Certificate in Microbiology in 1977. By 1979, he had completed his doctoral thesis (Dr. Odont./Ph.D.), a reflection of his rigorous scientific training and commitment to academic inquiry.

🧪 Professional Endeavors in Dental Science

Dr. Slots’ career spans both private practice and academia, beginning with clinical work in Copenhagen from 1969 to 1976. However, his true calling was in academia and research, where he quickly rose through the ranks at the Royal Dental College, becoming a tenured associate professor in the Department of Periodontology and Bacteriology. His academic influence extended internationally as he moved to the United States, joining the State University of New York at Buffalo (SUNYAB) as a visiting associate professor in 1977. His multifaceted roles there included teaching, research, and graduate mentorship. In 1982, his expertise was recognized with a professorial and chair appointment at the University of Göteborg in Sweden, where he led the Department of Oral Microbiology until 1986.

🔬 Contributions and Research Focus

Dr. Slots’ core research has focused on periodontal microbiology, particularly the microbial etiology of periodontal diseases and the role of anaerobic bacteria in oral infections. His extensive background in both clinical periodontology and microbiology enabled him to bridge these disciplines, pioneering investigations into microbial pathogenesis, host responses, and antimicrobial therapy. His work at the intersection of dentistry and microbiology has contributed significantly to the understanding of how bacterial biofilms influence periodontal health and disease progression. Through his positions in leading institutions, he has mentored countless students and young researchers in translational oral biology.

🏅 Accolades and Recognition

Throughout his distinguished career, Dr. Slots has earned numerous accolades that acknowledge both his scholarly achievements and teaching excellence. His academic journey includes obtaining a D.M.D. from the University of Pennsylvania in 1986, further consolidating his clinical credentials. In 1989, he expanded his skillset by earning an M.B.A. from the Wharton School, indicating his interest in healthcare administration and leadership. Such accomplishments reflect a rare blend of scientific acumen, clinical expertise, and administrative insight that is seldom seen in one individual. His tenured appointments and leadership roles speak volumes about the respect he commands in his field.

🌍 Impact and Global Influence

Dr. Slots’ contributions have had global implications, influencing not only North American dental education but also shaping European periodontal research. His tenure at institutions in Denmark, Sweden, and the United States illustrates his international standing and thought leadership. By combining laboratory science with clinical application, he has contributed to international standards in oral hygiene practices, periodontal disease diagnostics, and treatment protocols. His collaborative work across continents has helped create a robust, evidence-based approach to periodontal care that is taught and practiced worldwide.

📚 Legacy in Dental Education and Microbiology

As a graduate faculty member and department chair, Dr. Slots played a vital role in curriculum development, graduate training, and interdisciplinary integration of oral microbiology into mainstream dental education. He has influenced a generation of oral biologists and periodontists who continue to build upon his foundational work. His teaching style, grounded in research and clinical relevance, made him a beloved educator and mentor. The ripple effects of his academic stewardship can still be seen in the progressive research and pedagogical models employed at the University of Southern California and other leading dental institutions.

🔭 Future Vision and Continuing Relevance

Though his primary academic career has matured, the legacy of Dr. Slots remains very much alive in ongoing research studies, collaborative clinical trials, and academic dialogues. His integration of clinical practice with microbiological research stands as a model for future dental scientists aiming to address emerging challenges in oral-systemic health. With a unique blend of intellectual rigor and compassionate mentorship, Dr. Slots has laid a foundation that will support future breakthroughs in both academic and applied dental sciences. His life’s work continues to inspire innovation and scientific inquiry in oral health worldwide.

Publication

Polymerase chain reaction detection of 8 putative periodontal pathogens in subgingival plaque of gingivitis and advanced periodontitis lesions
A Ashimoto, C Chen, I Bakker, J Slots – 1996

Subgingival microflora and periodontal disease
J Slots – 1979

Periodontitis: facts, fallacies and the future
J Slots – 2017

Black-pigmented Bacteroides species, Capnocytophaga species, and Actinobacillus actinomycetemcomitans in human periodontal disease: virulence factors in colonization, survival
J Slots, RJ Genco – 1984

Bacteroides gingivalis, Bacteroides intermedius and Actinobacillus actinomycetemcomitans in human periodontal diseases
J Slots, MA Listgarten – 1988

Selective medium for isolation of Actinobacillus actinomycetemcomitans
J Slots – 1982

Actinobacillus actinomycetemcomitans in Human Periodontal Disease: a Cross-Sectional Microbiological Investigation
J Slots, HS Reynolds, RJ Genco – 1980

Diabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases
ILC Chapple, R Genco, Working Group 2 of the Joint EFP/AAP Workshop – 2013

The occurrence of Actinobacillus actinomycetemcomitans, Bacteroides gingivalis and Bacteroides intermedius in destructive periodontal disease in adults
J Slots, L Bragd, M Wikström, G Dahlén – 1986

Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in human periodontal disease: occurrence and treatment
J Slots, M Ting – 1999

Antibiotics in periodontal therapy: advantages and disadvantages
J Slots, TE Rams – 1990

The predominant cultivable microflora of advanced periodontitis
J Slots – 1977

Actinobacillus actinomycetemcomitans in Human Periodontal Disease: Prevalence in Patient Groups and Distribution of Biotypes and Serotypes Within Families
JJ Zambon, LA Christersson, J Slots – 1983

Systemic antibiotic therapy in periodontics
AJV Winkelhoff, TE Rams, J Slots – 1996

Microbial differences in 2 clinically distinct types of failures of osseointegrated implants
ES Rosenberg, JP Torosian, J Slots – 1991

The predominant cultivable organisms in juvenile periodontitis
J Slots – 1976

Suppression of the periodontopathic microflora in localized juvenile periodontitis by systemic tetracycline
J Slots, BG Rosling – 1983

Periodontal therapy in humans. I. Microbiological and clinical effects of a single course of periodontal scaling and root planing, and of adjunctive tetracycline therapy
J Slots, P Mashimo, MJ Levine, RJ Genco – 1979

Serology of oral Actinobacillus actinomycetemcomitans and serotype distribution in human periodontal disease
JJ Zambon, J Slots, RJ Genco – 1983

🏁 Conclusion

Dr. Jørgen Slots’ career stands as a remarkable example of interdisciplinary excellence in dental science. Through his research in periodontal microbiology, leadership in academic institutions, and dedication to global dental education, he has left a lasting legacy. His contributions have not only advanced scientific knowledge but also improved clinical approaches to oral healthcare worldwide. Dr. Slots remains a towering figure whose impact resonates in the fields of periodontology, microbiology, and beyond.

Georgia Kaiafa | Clinical Neuroscience | Best Researcher Award

Posted on by Neuroscientists

Assoc. Prof. Dr. Georgia Kaiafa | Clinical Neuroscience | Best Researcher Award

Assoc. Prof. Dr. Georgia Kaiafa, Medical School, Aristotle University of Thessaloniki,  Greece.

Dr. Georgia Kaiafa is a distinguished hematologist and academician whose career spans clinical excellence, impactful research, and dedicated teaching. A graduate of Aristotle University of Thessaloniki, she earned her MBBS in 1987, Board Certification in Hematology in 1996, and completed her Doctorate in 2005. Her academic roles have progressed from Lecturer to Associate Professor of Hematology and Thromboembolic Diseases, with a longstanding association at AHEPA University Hospital.

Profile

Scopus

 

🎓 Early Academic Pursuits

Georgia Kaiafa began her academic journey in medicine at the prestigious Aristotle University of Thessaloniki, enrolling in the Medical School in 1980. Her foundational training was marked by determination and intellectual rigor, culminating in the completion of her MBBS in 1987. A steadfast commitment to advanced education led her to earn her Board Certification in Haematology by 1996, and later, she successfully defended her Doctorate thesis in 2005. These formative years reflect her deep-rooted passion for understanding hematological science and its clinical applications.

🧬 Professional Endeavors in Hematology

Her professional journey has been nothing short of inspiring, anchored in both clinical excellence and academic growth. Georgia Kaiafa has served in several academic ranks, beginning as a Lecturer in Hematology from 2007 to 2015, advancing to Assistant Professor until 2021, and currently holding the esteemed position of Associate Professor of Hematology and Thromboembolic Diseases. She is affiliated with AHEPA University Hospital’s Hematology Department, a major center of excellence in Greece. Her expertise was further enriched by her tenure as a Visiting Research Associate at King’s College Hospital in London in 2012, where she gained valuable international exposure. Since 2005, she has also played a leadership role as a Coordinator in the Northern Greece Office of the Health Sector, bridging academic medicine and healthcare policy.

🩸 Contributions and Research Focus

Georgia Kaiafa has devoted her scholarly efforts to advancing the understanding of thrombosis, thromboembolic disorders, and hematological malignancies. With her contributions to over 95 peer-reviewed international journal publications and participation as a Principal Investigator in 26 research trials, she has carved out a niche in evidence-based hematological research. Her investigations have deeply influenced protocols and practices in vascular pharmacology, hematologic diagnostics, and the clinical management of thrombotic conditions. She is also a prominent educator, mentoring Ph.D. candidates and contributing to postgraduate programs for both Greek and international students.

🏆 Accolades and Recognition

Her scientific contributions have not gone unnoticed. Georgia Kaiafa has received significant national acclaim, including the 1st Prize Award for Best Paper at the Pan-Hellenic Haematology Conference in 2008 and again at the 1st Conference of Internal Medicine of Northern Greece in 2015. These accolades affirm her research excellence and clinical insight. Her expertise has earned her memberships in elite national and international medical societies, including the Hellenic Stroke Organization and the European Stroke Organization, as well as a respected position in the Excellence of Thrombosis initiative.

🌍 Impact and Influence

Beyond academia and clinical service, Kaiafa has exerted influence on multiple scientific fronts. As a reviewer for prominent journals such as Thrombosis Research, Anemia, Case Reports in Hematology, and the Indian Heart Journal, she ensures high scientific standards in hematologic research worldwide. Her editorial work for both international and Greek journals demonstrates her authority in the field and her dedication to the progression of scientific communication. Her wide-ranging collaborations and committee leadership roles have significantly influenced health education and medical research in Greece and abroad.

📚 Scholarly Engagement and Mentorship

Georgia Kaiafa is not only a prolific researcher but also a passionate mentor and academic contributor. With 23 chapters in medical books, over 130 abstracts in Greek conference proceedings, and nearly 100 abstracts presented in international forums, her voice resonates across the global hematology community. She has mentored and supervised numerous doctoral students, serving on committees for 12 Ph.D. projects and directly supervising five, cultivating the next generation of scientific minds. She has also chaired 22 congress sessions and delivered more than 100 invited talks, emphasizing her respected role as both speaker and thought leader.

🔬 Legacy and Future Contributions

As a seasoned academic and clinical researcher, Georgia Kaiafa continues to shape the future of hematology in Greece and beyond. Her legacy lies in her dual commitment to clinical care and scientific discovery, especially in the realm of thromboembolic diseases and hematologic innovations. Her ongoing involvement in research protocols, editorial responsibilities, and student mentorship assures that her influence will persist. With a solid foundation and a career marked by excellence, her future contributions are likely to further impact hematological sciences and translational medicine globally.

publication

 

  • Title: Monocyte Chemoattractant Protein-1 as a Biomarker in Acute Ischemic Stroke: A Prospective Pilot Study
    Author(s): [Not specified]
    Year: 2025

 

  • Title: Prospective Study of ADAMTS13 and von Willebrand Factor’s Role in the Prediction of Outcomes in Acute Ischemic Stroke
    Author(s): [Not specified]
    Year: 2025

 

  • Title: Antiphospholipid Syndrome: A Comprehensive Clinical Review
    Author(s): [Not specified]
    Year: [Not specified]

 

  • Title: The Seasonal Distribution of Immune Thrombotic Thrombocytopenic Purpura is Influenced by Geography: Epidemiologic Findings from a Multi-Center Analysis of 719 Disease Episodes
    Author(s): [Not specified]
    Year: 2024

 

  • Title: Current Trends in Stroke Biomarkers: The Prognostic Role of S100 Calcium-Binding Protein B and Glial Fibrillary Acidic Protein
    Author(s): [Not specified]
    Year: [Not specified]

 

  • Title: Outpatient Management After Hospitalisation for Acute Decompensation of Cirrhosis: A Practical Guide
    Author(s): [Not specified]
    Year: 2024

 

  • Title: Which Is the Best Way to Treat Massive Hemoptysis? A Systematic Review and Meta-Analysis of Observational Studies
    Author(s): [Not specified]
    Year: [Not specified]

 

  • Title: Post-COVID-19 and Irritable Bowel Syndrome: A Literature Review
    Author(s): [Not specified]
    Year: [Not specified]

 

  • Title: Thyroid Disease and Systemic Lupus Erythematosus
    Author(s): [Not specified]
    Year: 2023

 

🏁 Conclusion

Dr. Georgia Kaiafa embodies the values of academic integrity, scientific advancement, and clinical leadership. Her commitment to both national healthcare development and international scientific collaboration sets her apart. With a strong foundation in research, education, and public health, she not only meets but exceeds the criteria for recognition through the Best Researcher Award. Her body of work stands as a testament to sustained excellence and future promise in hematology and related disciplines.

ROSA MOURAO | Neuropharmacology | Women Researcher Award

Posted on by Neuroscientists

Prof. Dr. ROSA MOURAO | Neuropharmacology | Women Researcher Award

Prof. Dr. ROSA MOURAO, UNIVERSIDADES FEDERAL DO OESTE DO PARÁ, Brazil.

Prof. Dr. Rosa Helena Veras Mourão is a distinguished Brazilian biochemist and full professor at UFOPA, with a strong academic foundation in Biological Sciences and Plant Biochemistry. She earned her Ph.D. in Biological Sciences from the Federal University of Pernambuco, including a research fellowship at UNICAMP under Prof. Dr. Mário Saad. Her research centers on the biochemical properties of Amazonian medicinal plants, focusing on diabetes, anti-inflammatory and antimicrobial activities, essential oils, and the effects of Bothrops atrox venom.

Profile

Orcid

🎓 Early Academic Pursuits

Rosa Helena Veras Mourão embarked on her scientific journey with a Bachelor’s degree in Biological Sciences from the Federal University of Ceará in 1993. Her early academic choices reflected a deep curiosity about the natural world, especially the biochemical aspects of plant life. She soon pursued a Master’s degree in Plant Biochemistry at the same institution, which she completed in 1996. Her growing interest in health-related plant biochemistry led her to a doctoral program in Biological Sciences at the Federal University of Pernambuco, awarded in 2006. During her Ph.D., she was selected for a prestigious sandwich fellowship at the State University of Campinas (UNICAMP), where she conducted research under the guidance of Prof. Dr. Mário Saad, further sharpening her expertise in metabolic disorders like diabetes.

🧪 Professional Endeavors in Biochemistry

Currently a Full Professor at the Institute of Collective Health at the Federal University of Western Pará (UFOPA), Prof. Mourão has built a solid career blending academic research with community outreach. Her expertise lies in Biochemistry, particularly medicinal plants and their applications in treating chronic diseases. Her work consistently merges scientific rigor with social relevance, focusing on diabetes, antimicrobial resistance, anti-inflammatory responses, and the effects of Bothrops atrox venom. She has mentored numerous Master’s students through UFOPA’s Health Sciences and Natural Resources programs and also advises Ph.D. candidates under the REDE BIONORTE initiative, reflecting her pivotal role in academic mentorship and capacity building in the Amazon region.

🌿 Contributions and Research Focus

Prof. Mourão’s research delves into the pharmacological potential of Amazonian flora, particularly essential oils and plant extracts with therapeutic effects. Her contributions include advancing the standardization of bioactive extracts, evaluating their antimicrobial and anti-inflammatory properties, and assessing their applicability in the treatment of diabetes. Her scientific investigations into Bothrops atrox venom have added critical insights to toxinology. Furthermore, her interdisciplinary approach bridges biochemistry with ethnopharmacology, respecting traditional knowledge systems while applying rigorous scientific methods to validate their efficacy.

🏅 Accolades and Recognition

Her commitment to research excellence earned her the prestigious CNPq Research Productivity Fellowship (PQ2), which she held until 2023. This national recognition highlighted her sustained contributions to Brazilian science, particularly in the fields of medicinal chemistry and natural products. In academic circles, her name appears under various bibliographic formats such as MOURÃO, R.H.V. and Rosa H. Mourão, indicating her prolific and diverse scholarly output. She is also active on national platforms such as the Lattes Curriculum system and holds an ORCID iD, further ensuring her work’s visibility and impact within global research communities.

🌎 Impact and Social Innovation

Beyond academia, Prof. Mourão is deeply involved in projects that fuse scientific knowledge with social innovation. She co-founded Deveras Amazônia, a startup that transforms Amazonian biodiversity into culinary experiences, and Xibé Oficial, a fashion-focused enterprise using natural dyes extracted from Amazonian plants. Her technological extension projects with local communities in Western Pará demonstrate her commitment to applying scientific research for social impact, focusing on sustainable development and strengthening regional production chains. Her work empowers Amazonian communities by integrating traditional knowledge with entrepreneurial strategies.

🔬 Legacy in Scientific Mentorship

Throughout her academic career, Prof. Mourão has mentored a generation of scientists who now contribute to fields as diverse as biochemistry, pharmacognosy, and public health. As a Master’s and Ph.D. advisor, she fosters critical thinking, innovation, and social responsibility in her students. Her guidance helps shape professionals capable of addressing both local health challenges and broader scientific questions. Her legacy lies not only in her publications and projects but also in the human capital she has developed over decades of service.

🌱 Future Contributions and Vision

Looking ahead, Prof. Rosa Helena Veras Mourão remains a beacon of interdisciplinary research in the Amazon. Her vision includes expanding collaborations that promote bioeconomic development rooted in sustainability, enhancing the integration of indigenous knowledge systems into mainstream science, and scaling up social-impact projects. With her strong academic foundation and unwavering dedication to public health and biodiversity, she continues to serve as an inspiring force in Brazilian science, forging a future where innovation, ecology, and equity go hand in hand.

Publication

1. Antifungal chemosensitization through induction of oxidative stress: A model for control of candidiasis based on the Lippia origanoides essential oil
Authors: Sandra Layse F. Sarrazin, Jean-Paul Bourdineaud, José Guilherme S. Maia, Rosa Helena V. Mourão, Ricardo B. Oliveira
Year: 2024

2. Lip balm made from butter extracted from bacuri (Platonia insignis Mart.) Amazonian fruit seeds: Development and characterization
Authors: Bruna Carvalho Cantal de Souza, Walberson da Silva Reatgui, Junior Avelino de Araújo, Rosa Helena Veras Mourão, Leopoldo C. Baratto, Gabriela B. dos Santos, Kariane M. Nunes
Year: 2024

3. Volatile Constituents of Some Myrtaceous Edible and Medicinal Fruits from the Brazilian Amazon
Authors: Adenilson S. Barroso, Lais T. Massing, Chieno Suemitsu, Rosa Helena V. Mourão, Pablo L. B. Figueiredo, José Guilherme S. Maia
Year: 2024

4. Molecular modelling and anticholinesterase activity of the essential oil from three chemotypes of Lippia alba (Mill.)
Authors: Antônio Q. Silva Júnior, Gabriela dos Santos Rodrigues, Karina A. de Sousa, Leoneide E. M. Bouillet, Gabriela B. dos Santos, Adenilson S. Barroso, Rosa Helena Veras Mourão
Year: 2024

5. Seasonal Variation in Essential Oil Composition and Antioxidant Capacity of Aniba canelilla
Authors: Ellen de Nazaré S. da Cruz, Luana de Sousa P. Barros, Bruna de Araújo Guimarães, Rosa Helena V. Mourão, José Guilherme S. Maia, William N. Setzer, Joyce Kelly da Silva, Pablo L. B. Figueiredo
Year: 2023

6. Distribution of Carapa Guianensis Associated to Topoclimatic Variables Indicating Potential Clusters for Cultivation in the State of Pará
Authors: Denison Lima Correa, Lucieta G. Martorano, Leila Sheila S. Lisboa, Carlos T. dos S. Dias, Alberdan S. Santos, Rosa Helena V. Mourão
Year: 2023

7. Seasonal Influence on Volatile Composition of Psidium friedrichsthalianum Leaves, Sampled in the Brazilian Amazon
Authors: Paulo V. L. Santos, Ellen de N. S. da Cruz, Jennifer de A. Nunes, Rosa Helena V. Mourão, Walnice M. O. do Nascimento, José Guilherme S. Maia, Pablo L. B. Figueiredo
Year: 2023

8. Seasonal Variability of a Caryophyllane Chemotype Essential Oil of Eugenia patrisii Vahl Occurring in the Brazilian Amazon
Authors: Ellen de N. S. da Cruz, Luana de S. Peixoto, Jamile S. da Costa, Rosa Helena V. Mourão, Walnice M. O. do Nascimento, José Guilherme S. Maia, William N. Setzer, Joyce Kelly da Silva, Pablo L. B. Figueiredo
Year: 2022

9. Atividade antioxidante de extratos de Myrciaria dubia (camu-camu)
Authors: Carlena Sinara M. da Silva, Rosa Helena Veras Mourão
Year: 2022

10. Myrciaria dubia (Kunth) McVaugh (Myrtales: Myrtaceae): análise dos produtos elaborados a partir do seu fruto
Authors: Carlena Sinara M. da Silva, Rosa Helena Veras
Year: 2021

🧾 Conclusion

Prof. Rosa Helena Veras Mourão exemplifies a modern scientist whose work harmonizes rigorous biochemical research with social and environmental impact. Her commitment to advancing science in the Amazon, empowering communities, and nurturing future scholars positions her as a transformative figure in Brazilian research. Her legacy is defined not only by academic excellence but also by her visionary efforts to blend innovation with inclusivity, ensuring that science serves both nature and society.

Hongrui Meng | Neurodegenerative disease | Excellence in Research Award

Posted on by Neuroscientists

Prof. Dr. Hongrui Meng | Neurodegenerative disease | Excellence in Research Award

Prof. Dr. Hongrui Meng,  Institute of Neuroscience, Soochow University, China.

Dr. Hongrui Meng is a highly accomplished neuroscientist whose academic path began with a Ph.D. in Behavioural Neuroscience from Hamamatsu University School of Medicine in Japan. He later conducted postdoctoral research in molecular neurobiology and human genetics at Juntendo University, Tokyo. Currently a professor at the Institute of Neuroscience, Soochow University, Dr. Meng leads a research team dedicated to uncovering the molecular and mitochondrial mechanisms underlying Parkinson’s disease and ALS. His work spans high-impact research projects funded by JSPS, NSFC, and other prestigious bodies. In addition to numerous scientific publications, he has contributed to diagnostic innovation through patented miRNA detection methods. His influence extends beyond academia through translational applications such as wearable technologies for Parkinson’s symptom monitoring.

Profile

Orcid

🎓 Early Academic Pursuits

Dr. Hongrui Meng began his distinguished academic journey in the field of neuroscience by earning his Ph.D. in Behavioural Neuroscience from the prestigious Hamamatsu University School of Medicine in Japan. His early education and training laid a strong foundation in experimental neuroscience, with a focus on the behavioral manifestations of neurodegenerative conditions. These formative years not only sharpened his scientific curiosity but also equipped him with the cross-disciplinary expertise to address complex neurological questions.

🧠 Professional Endeavors

Following his doctoral studies, Dr. Meng advanced his specialization through postdoctoral training in molecular neurobiology and human genetics at Juntendo University in Tokyo. There, he immersed himself in high-level research focusing on the genetic underpinnings of neurological disorders. His competence and dedication soon earned him a faculty appointment as an Assistant Professor in the Department of Research for Neurodegenerative Diseases and Dementia. His professional arc reached a significant milestone in 2020 when he was promoted to Full Professor and moved to the Institute of Neuroscience at Soochow University, where he now leads the Laboratory of Molecular Neurology.

🧬 Contributions and Research Focus

Dr. Meng’s scientific contributions center on the molecular mechanisms of Parkinson’s disease and amyotrophic lateral sclerosis (ALS). His research bridges mitochondrial dysfunction, alpha-synuclein aggregation, and neurodegeneration. He has completed pivotal studies supported by the Japan Society for the Promotion of Science and the Takeda Pharmaceutical Foundation, delving into the role of CHCHD2 gene mutations and mitochondrial pathways. His ongoing projects funded by the National Natural Science Foundation of China (NSFC) explore mitochondrial unfolded protein responses (mtUPR), while another innovative project in Suzhou focuses on wearable technology for monitoring Parkinson’s disease symptoms—demonstrating his commitment to translational and patient-centered neuroscience.

🔬 Innovation and Scientific Output

A notable innovator, Dr. Meng has made strides in molecular diagnostic technologies. His work has led to the development of high-throughput RT-qPCR-based methods for detecting primary and precursor miRNAs, contributing to enhanced genetic analysis of neurodegenerative disorders. He holds a patent granted in South Africa and another under process in China, underscoring his role at the intersection of research and technology. Furthermore, his publications in highly regarded journals like Current Issues in Molecular Biology and Cell Communication and Signaling reflect a consistent record of impactful findings that inform both fundamental neuroscience and clinical approaches.

🏅 Accolades and Recognition

Dr. Meng’s ascent in the academic community has been marked by numerous grants, including multiple from the JSPS and NSFC, attesting to the trust placed in his research vision by top funding bodies. While a formal list of awards may be under-documented, his rapid progression from postdoctoral fellow to professor and research team leader in less than a decade speaks volumes about his recognition among peers and institutional leadership. His leadership in multi-disciplinary and international collaborations is an implicit accolade of his scientific reliability and visionary perspective.

🌍 Impact and Influence

Through his groundbreaking work on mitochondrial mechanisms and neurodegeneration, Dr. Meng is helping to reshape current understanding of Parkinson’s disease pathophysiology. His investigations into alpha-synucleinopathy and microglial disruption have provided fresh insights into cellular degeneration and neuroimmune interactions. Beyond academia, his involvement in developing wearable diagnostic tools highlights his drive to impact patient lives directly. As a consultant on neuroprotective treatments such as PD-018/19, he bridges the academic and pharmaceutical worlds to accelerate therapeutic discovery.

🔮 Legacy and Future Contributions

Looking forward, Dr. Meng is poised to be a leading figure in neurogenetic diagnostics and therapeutic innovation. His laboratory at Soochow University serves as an incubator for future discoveries in neurodegenerative disease mechanisms, and his continued work in mitochondrial research promises to inform emerging therapies. With a growing publication record, international patents, and a robust research pipeline, Dr. Meng’s legacy will be one of bridging basic neuroscience with clinical application—paving the way for novel interventions and a better understanding of brain disorders in the molecular era.

Publication

 

  • Title: Dicer Is Involved in Cytotoxicity and Motor Impairment Induced by TBPH Deficiency
    Authors: Xiang Long, Yijie Wang, Hongrui Meng
    Year: 2025

 

  • Title: Transcriptomic analysis of lipid metabolism genes in Alzheimer’s disease: highlighting pathological outcomes and compartmentalized immune status
    Authors: Sun Y., Zhang Y., Jiang M., Long X., Miao Y., Du H., Zhang T., Meng H., Ma X.
    Year: 2024

 

  • Title: CHCHD2 P14L, found in amyotrophic lateral sclerosis, exhibits cytoplasmic mislocalization and alters Ca2+ homeostasis
    Authors: Aya Ikeda, Hongrui Meng, Daisuke Taniguchi, Muneyo Mio, Manabu Funayama, Kenya Nishioka, Mari Yoshida, Yuanzhe Li, Hiroyo Yoshino, Tsuyoshi Inoshita et al.
    Year: 2024

 

  • Title: TDP-43 mutations-induced defects in miRNA biogenesis and cytotoxicity by differentially obstructing Dicer activity in Drosophila and in vitro
    Authors: Xiang Long, Mengni Jiang, Yongzhen Miao, Huanhuan Du, Ting Zhang, Zhuoya Ma, Jiao Li, Chunfeng Liu, Hongrui Meng
    Year: 2024

 

  • Title: A Simple Technique to Assay Locomotor Activity in Drosophila
    Authors: Long X., Du H., Jiang M., Meng H.
    Year: 2023

 

  • Title: Functional MHCI deficiency induces ADHD-like symptoms with increased dopamine D1 receptor expression
    Authors: Meng H.-R., Suenaga T., Edamura M., Nakahara D., Murakami G., Fukuda A., Ishida Y.
    Year: 2021

 

  • Title: Light-driven activation of mitochondrial proton-motive force improves motor behaviors in a Drosophila model of Parkinson’s disease
    Authors: Imai Y., Hattori N., Inoshita T., Shiba-Fukushima K., Meng H., Hara K.Y., Sawamura N.
    Year: 2019

 

  • Title: Mutations in CHCHD2 cause α-synuclein aggregation
    Authors: Ikeda A., Nishioka K., Takanashi M., Li Y., Mori A., Okuzumi A., Izawa N., Ishikawa K.-I., Funayama M., Imai Y. et al.
    Year: 2019

 

  • Title: Parkinson’s disease-associated iPLA2-VIA/PLA2G6 regulates neuronal functions and α-synuclein stability through membrane remodeling
    Authors: Mori A., Hatano T., Koinuma T., Kubo S.-I., Spratt S., Yamashita C., Okuzumi A., Imai Y., Hattori N., Inoshita T. et al.
    Year: 2019

 

  • Title: Twin CHCH proteins, CHCHD2, and CHCHD10: Key molecules of Parkinson’s disease, amyotrophic lateral sclerosis, and frontotemporal dementia
    Authors: Imai Y., Hattori N., Meng H., Shiba-Fukushima K.
    Year: 2019

 

🧾 Conclusion

Dr. Hongrui Meng’s career reflects a dynamic blend of academic excellence, molecular research innovation, and translational neuroscience. His scientific endeavors have not only enriched the understanding of neurodegenerative diseases but have also paved the way for novel diagnostic and therapeutic strategies. With a growing portfolio of impactful research, patents, and leadership in neurobiology, Dr. Meng stands out as a driving force in the global fight against neurological disorders. His work promises continued contributions to neuroscience with lasting influence on both scientific knowledge and patient care.

 

Joice Margareth de Almeida Rodolpho | Molecular Neuroscience | Best Researcher Award

Posted on by Neuroscientists

Mrs. Joice Margareth de Almeida Rodolpho | Molecular Neuroscience | Best Researcher Award

Mrs. Joice Margareth de Almeida Rodolpho, Universidade Federal de São Carlos, Brazil.

Joice Margareth de Almeida Rodolpho is a dedicated Brazilian researcher with a strong foundation in biotechnology, parasitology, immunology, and molecular biology. She earned her Master’s and Ph.D. from the Federal University of São Carlos (UFSCar), where she explored the role of eosinophils as antigen-presenting cells in parasitic infections like Toxocara canis and Schistosoma mansoni. Her work is recognized for integrating experimental immunology with therapeutic innovations, such as the evaluation of natural plant extracts and nanomaterials for infection control. She further specialized in Flow Cytometry and Oncohematology, enhancing her analytical capabilities. With multiple awards and citations, her impactful contributions continue to strengthen Brazil’s standing in parasitological and immunological research.

Profile

Orcid

🎓 Early Academic Pursuits

Joice Margareth de Almeida Rodolpho began her academic journey in Brazil, developing a strong foundation in the life sciences. Her early interest in molecular biology and parasitology led her to pursue advanced studies at the esteemed Universidade Federal de São Carlos (UFSCar). She earned her Master’s degree in Biotechnology between 2009 and 2012, conducting significant research on Toxocara canis, particularly on the phenotypic characterization of eosinophils as antigen-presenting cells. This early work not only revealed her meticulous scientific inquiry but also laid the groundwork for her deeper exploration into immunology.

🧬 Professional Endeavors in Molecular and Evolutionary Genetics

Driven by a passion for understanding immune responses, Joice pursued a Ph.D. in Evolutionary Genetics and Molecular Biology at UFSCar from 2013 to 2017. Her doctoral research focused on the role of eosinophils as antigen-presenting cells both in vitro and ex vivo, offering vital insights into host-parasite interactions and immune regulation. Her work during this period was supported by a prestigious FAPESP scholarship, demonstrating her academic excellence and the relevance of her contributions. Under the mentorship of Professor Fernanda de Freitas Anibal, Joice refined her skills in experimental immunology and cellular biology.

🧪 Contributions and Research Focus in Parasitology and Immunopathology

Joice Rodolpho’s primary research interests lie at the intersection of parasitology, cellular immunology, and experimental pathology. Her studies explore how parasitic infections, such as those caused by Schistosoma mansoni and Toxocara canis, affect immune cell function, especially eosinophils. She has also contributed to investigations into natural plant extracts, like Mentha piperita L., assessing their therapeutic potential in modulating parasitic infections. Moreover, she extended her expertise to the field of nanomaterials, evaluating the cytotoxicity and cell death mechanisms induced by compounds like Ag₂WO₄, thus bridging classical parasitology with emerging biomedical technologies.

🏅 Accolades and Recognition in Scientific Circles

Throughout her career, Joice has received several recognitions that reflect the impact and originality of her research. In 2010, she was honored with a Menção Honrosa (Honorable Mention) for her work on Mentha piperita L. in treating Schistosoma mansoni, earning 2nd place in diagnostics and treatment. She continued to gain academic acclaim with awards at major conferences, including the VI Congresso da Sociedade Paulista de Parasitologia (2012) and the XXII B-MRS Meeting in 2024, highlighting her work on cytotoxic responses and innovative parasitological control methods. In 2024, her project on the parasitological and pathological evaluation of AW-HRL-C for schistosomiasis control was notably recognized by UNIFESP.

🧠 Impact and Influence in Experimental Immunology

Joice’s dedication to experimental immunology and cytometry has allowed her to mentor and influence upcoming researchers, especially in specialized fields such as flow cytometry. Her recent specialization in Immunology and Oncohematology by Flow Cytometry (2021–2022) at IPESSP further enriched her profile, showcasing her commitment to continuous learning and application of advanced technologies in immune profiling. Her ability to merge classical immunopathology with state-of-the-art cytometric tools reflects her versatility and forward-thinking scientific approach.

🌱 Legacy and Future Contributions in Biomedical Science

Poised to make lasting contributions, Joice Margareth de Almeida Rodolpho stands at the forefront of research into host-pathogen interactions, parasitic disease management, and immune cell function modulation. Her unique interdisciplinary approach—integrating molecular biology, natural product pharmacology, and immunological techniques—positions her as a valuable contributor to both academic research and potential therapeutic advancements. She is expected to lead innovative research in the treatment of neglected tropical diseases and immunological disorders, with implications for global health.

🔬 Research Field Relevance and Scientific Identity

As a scholar deeply embedded in the Brazilian scientific ecosystem, Joice’s identity is reflected in her multiple citation forms, indicating her widespread academic collaborations and international visibility. Her expertise bridges evolutionary genetics, biotechnology, cytometry, and immunoparasitology—making her a multifaceted researcher. Her contributions are cited under various names such as “RODOLPHO, JOICE M. A.” and “Joice Margareth de Almeida Rodolpho,” reflecting a robust presence in scholarly literature and ensuring her work continues to guide parasitological and immunological research for years to come.

Publication

  • Title: Biomarkers and Mental Disorders: A Relevance Analysis Using a Random Forest Algorithm
    Authors: Joice M. A. Rodolpho; Krissia F. Godoy; Bruna D. L. Fragelli; Jaqueline Bianchi; et al.
    Year: 2025

 

  • Title: Death Risk Score Model of Hospitalized COVID‐19 Patients: A Cohort Study
    Authors: Gustavo A. Cruz; Thais B. Boteon; Henrique Pott; Joice M. A. Rodolpho; et al.
    Year: 2025

 

  • Title: Synergistic Antifungal Effect and In Vivo Toxicity of a Monoterpene Isoespintanol Obtained from Oxandra xylopioides Diels
    Authors: Orfa I. C. Martínez; Alberto Angulo; Joice Rodolpho; Krissia F. Godoy; et al.
    Year: 2024

 

  • Title: Synergistic Antifungal Effect and In Vivo Toxicity of the Monoterpene Isoespintanol Obtained from Oxandra xylopioides Diels (Preprint)
    Authors: Orfa I. C. Martínez; Alberto Angulo; Joice M. A. Rodolpho; et al.
    Year: 2024

 

  • Title: Carbon Black CB-EDA Nanoparticles in Macrophages: Changes in the Oxidative Stress Pathway and in Apoptosis Signaling
    Authors: Joice M. A. Rodolpho; Krissia F. Godoy; Bruna D. L. Fragelli; et al.
    Year: 2023

 

  • Title: HGPRT and PNP: Recombinant Enzymes from Schistosoma mansoni and Their Role in Immunotherapy during Experimental Murine Schistosomiasis
    Authors: Bruna D. L. Fragelli; Ana C. Fattori; Joice M. A. Rodolpho; et al.
    Year: 2023

 

  • Title: Titanium Dioxide Nanoparticle (TiO2 NP) Induces Toxic Effects on LA-9 Mouse Fibroblast Cell Line
    Authors: Ana C. M. Fattori; Patricia Brassolatti; Joice M. A. Rodolpho; et al.
    Year: 2023

 

  • Title: Analysis of Cytotoxicity and Genotoxicity in a Short-Term Dependent Manner Induced by a New Titanium Dioxide Nanoparticle in Murine Fibroblast Cells
    Authors: Pedrino, M.; Brassolatti, P.; Joice M. A. Rodolpho; et al.
    Year: 2022

 

  • Title: Functionalized Titanium Nanoparticles Induce Oxidative Stress and Cell Death in Human Skin Cells
    Authors: Brassolatti, P.; Joice M. A. Rodolpho; Krissia F. Godoy; et al.
    Year: 2022

 

  • Title: Toxicological Effects of the Mixed Iron Oxide Nanoparticle (Fe₃O₄ NP) on Murine Fibroblasts LA-9
    Authors: Alves Feitosa, K.; Joice M. A. Rodolpho; et al.
    Year: 2022

 

🧾 Conclusion

Joice Rodolpho’s academic journey and scientific contributions reveal a researcher of high caliber, committed to advancing our understanding of host-pathogen dynamics and immune system function. Her work, grounded in rigorous experimentation and innovation, holds promise for developing novel therapies for neglected tropical diseases. With a forward-looking approach and interdisciplinary expertise, she stands out as a key contributor in biomedical science, poised to influence future discoveries in immunopathology and disease control.

Jagadeesh Rao | Neuropharmacology | Best Researcher Award

Posted on by Neuroscientists

Dr. Jagadeesh Rao | Neuropharmacology | Best Researcher Award

Dr. Jagadeesh Rao,  IGC Pharma LLC, United States.

Dr. Jagadeesh S. Rao is a distinguished neuroscientist and clinical researcher with over 15 years of experience in neuroscience, psychiatry, neuropharmacology, and drug development. His career is marked by significant contributions to the understanding and treatment of neurodegenerative diseases, especially Alzheimer’s disease. With a strong academic foundation in molecular biology and biochemistry, Dr. Rao has led groundbreaking work in clinical trial design, preclinical toxicology, and regulatory submissions, including IND and CMC documentation for FDA approvals. He currently serves as Principal Scientist at IGC Pharma Inc., where he leads teams in Phase I and II clinical trials, manages CROs and budgets, and has developed both OTC and investigational drug products.

Profile

Orcid

🧠 Early Academic Pursuits

Dr. Jagadeesh S. Rao began his scientific journey with a deep interest in the complexities of the human brain and molecular biology. From the early stages of his academic training, he demonstrated exceptional dedication to exploring the interplay between neurobiology, biochemistry, and psychiatric health. His pursuit of a Ph.D. laid a robust foundation in neuroscience and neuropharmacology, equipping him with a multidisciplinary understanding of the cellular and molecular mechanisms that underlie neurodegenerative and neuropsychiatric disorders. This strong academic grounding would later become the driving force behind his innovative contributions to research in pain, Alzheimer’s disease, and drug development.

🧪 Professional Endeavors in Neuroscience and Drug Development

With over 15 years of professional experience, Dr. Rao has successfully navigated and led multiple domains including toxicology, psychiatry, and molecular biology. Currently serving as a Principal Scientist at IGC Pharma Inc., he has taken a prominent role in advancing clinical drug development, particularly in designing and executing Phase I and II trials. His expertise extends to critical regulatory processes such as Investigational New Drug (IND) submissions, clinical protocol design, and Chemistry, Manufacturing, and Controls (CMC). He has actively led teams in drug formulation, batch production, validation, and compliance with FDA and ISO standards—demonstrating a blend of scientific acumen and regulatory insight.

🧬 Contributions and Research Focus in Neuropharmacology

Dr. Rao’s research centers on developing therapeutic interventions for neurodegenerative and neuropsychiatric conditions, especially Alzheimer’s disease. His contributions span the full spectrum of drug development: from preclinical toxicology and pharmacokinetics to clinical pharmacodynamics and regulatory documentation. He has designed preclinical studies adhering to GLP standards, involving mutagenesis assays, reproductive and general toxicity assessments, and immunogenicity tests. Moreover, he played a key role in the development of over-the-counter (OTC) pain relief cream products, contributing both to academic research and commercial innovation. His insights into P450 enzyme polymorphisms and their effects on drug metabolism showcase a precision medicine approach to pharmacological care.

🏅 Accolades and Recognition in Clinical Research

While much of Dr. Rao’s work has been behind the scenes of scientific advancement and regulatory excellence, his leadership in preparing CMC documents and overseeing investigational drug submissions has earned him widespread respect among peers. His oversight of departmental budgets and his management of Clinical Research Organizations (CROs) reflect not only scientific brilliance but also strategic and financial stewardship in clinical drug development. The successful initiation of Phase I and II clinical trials under his guidance stands as a testament to his expertise and diligence in the field.

🌍 Impact and Influence in Translational Medicine

Dr. Rao’s work bridges the gap between laboratory research and clinical application. His projects have advanced the translational medicine field by offering therapeutic candidates that move seamlessly from preclinical safety assessments to human trials. His influence is felt not only through the innovative drugs developed under his watch but also in shaping protocols that align with FDA’s stringent regulatory frameworks. His understanding of the molecular intricacies of neuropsychiatric diseases allows him to propose and test interventions that directly respond to the unmet needs of patients and healthcare systems alike.

🔬 Legacy in Scientific Rigor and Innovation

One of Dr. Rao’s enduring legacies lies in his rigorous approach to clinical pharmacology and his commitment to quality and safety in every phase of drug development. His ability to interpret complex PK/PD data, assess drug-drug interactions, and foresee adverse events has significantly shaped safer and more effective drug protocols. He has also contributed to the creation of technical documentation and risk assessments that serve as gold standards in the field, ensuring compliance and reproducibility for future scientists and clinicians.

🚀 Future Contributions and Vision for Neurotherapeutics

Looking ahead, Dr. Rao continues to pave the way in neurotherapeutics with a focused ambition to develop treatments for cognitive and behavioral disorders rooted in neuroinflammation and synaptic dysfunction. His vision includes refining clinical strategies using personalized medicine models and leveraging his expertise in biochemistry and molecular neuropharmacology. As the global demand for effective neurological therapies increases, Dr. Rao’s evolving research and leadership promise to yield transformative solutions that will benefit countless patients worldwide.

Publication

1. Title: Neurobiological alteration in agitation in Alzheimer’s disease and possible interventions
Author(s): Rao, Jagadeesh S.; Tangarife, Maria Alejandra; Mukunda, Ram
Year: 2024

2. Title: Effects of chronic clozapine administration on markers of arachidonic acid cascade and synaptic integrity in rat brain
Author(s): Kim, Hyung-Wook; Cheon, Yewon; Modi, Hiren R.; Rapoport, Stanley I.; Rao, Jagadeesh S.
Year: 2012

3. Title: Epigenetic modifications in frontal cortex from Alzheimer’s disease and bipolar disorder patients
Author(s): Rao, J. S.; Keleshian, V. L.; Klein, S.; Rapoport, S. I.
Year: 2012

4. Title: Gabapentin’s minimal action on markers of rat brain arachidonic acid metabolism agrees with its inefficacy against bipolar disorder
Author(s): Reese, Edmund A.; Cheon, Yewon; Ramadan, Epolia; Kim, Hyung-Wook; Chang, Lisa; Rao, Jagadeesh S.; Rapoport, Stanley I.; Taha, Ameer Y.
Year: 2012

5. Title: Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: implications for its efficacy in bipolar disorder
Author(s): Ramadan, Epolia; Basselin, Mireille; Rao, Jagadeesh S.; Chang, Lisa; Chen, Mei; Ma, Kaizong; Rapoport, Stanley I.
Year: 2012

6. Title: Altered Expression of G-protein subunits and GRKs in Alzheimer’s Disease
Author(s): Reese, Edmund A.; Kim, Hyung-Wook; Rapoport, Stanley I.; Rao, Jagadeesh S.
Year: 2011

7. Title: Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin E₂ concentration in rat brain
Author(s): Cheon, Yewon; Park, Jee-Young; Modi, Hiren R.; Kim, Hyung-Wook; Lee, Ho-Joo; Chang, Lisa; Rao, Jagadeesh S.; Rapoport, Stanley I.
Year: 2011

8. Title: Dietary n-6 PUFA deprivation downregulates arachidonate but upregulates docosahexaenoate metabolizing enzymes in rat brain
Author(s): Kim, Hyung-Wook; Rao, Jagadeesh S.; Rapoport, Stanley I.; Igarashi, Miki
Year: 2011

9. Title: Disturbed Choline Plasmalogen and Phospholipid Fatty Acid Concentrations in Alzheimer’s Disease Prefrontal Cortex
Author(s): Igarashi, Miki; Ma, Kaizong; Gao, Fei; Kim, Hyung-Wook; Rapoport, Stanley I.; Rao, Jagadeesh S.
Year: 2011

10. Title: Olanzapine Decreases Brain Arachidonic Acid (AA) Metabolism in Rats by Reducing Plasma Availability of AA
Author(s): Cheon, Yewon; Modi, Hiren R.; Park, Jee-Young; Kim, Hyung-Wook; Chang, Lisa; Rao, Jagadeesh S.; Rapoport, Stanley I.
Year: 2011

✅Conclusion

Dr. Rao’s career reflects a powerful blend of scientific innovation, regulatory excellence, and clinical insight. His dedication to developing safe and effective neurological therapeutics has significantly advanced the field of translational medicine. As a leader, mentor, and researcher, his ongoing work continues to influence modern approaches to treating complex brain disorders, setting a high standard for future neuropharmacological research and therapeutic innovation.

Liliana Elena Weimer | Clinical Neuroscience | Best Researcher Award

Posted on by Neuroscientists

Dr. Liliana Elena Weimer | Clinical Neuroscience | Best Researcher Award

Dr.  Liliana Elena Weimer, Center For Global Health Istituto Superiore di Sanita’ Rome, Italy.

Dr. Liliana Elena Weimer is a highly accomplished physician and clinical researcher , where she has risen to the prestigious Level II “First Researcher” position. Her professional focus lies in clinical trials for infectious diseases, particularly HIV and Hepatitis C. She has played a critical role in major national and international research efforts, including collaborations with the U.S. Clinical Trials Group and leadership of the large-scale PITER cohort involving 25,000 HCV patients. She is known not only for her scientific contributions but also for her humanitarian efforts during the COVID-19 emergency. Among her recognitions is the 1st Prize at the 2019 International Congress on Hepatitis C in Seville. Throughout her career, she has exemplified scientific integrity, dedication, and service to public health.

Profile

Google Scholar

🎓 Early Academic Pursuits

Born on December 19, 1965, in Buenos Aires to Italian parents, Dr. Liliana Elena Weimer embraced her dual heritage and committed herself to a life in medicine and research. With Italian citizenship and deep academic determination, she laid the groundwork for her career by studying medicine, ultimately finding her professional home in Italy. Her academic path, though not fully detailed, clearly led her toward a focus on clinical medicine and infectious diseases, with her earliest professional roles marking the beginning of a lifelong engagement in public health and biomedical research. Her intellectual dedication and international roots later became an asset in global research collaborations.

🩺 Professional Endeavors

Dr. Weimer’s distinguished career spans over three decades at the Italian National Institute of Health (ISS), beginning in 1985. Starting as a dedicated clinical physician, she ascended to Level III researcher status by 1990 and continued to grow into higher ranks, culminating in her success in the national Art. 15 competition for the Level II “First Researcher” role in 2022, officially backdated to 2021. Throughout her tenure at ISS, she became a central figure within the Global Health Center in Rome. Known for her tireless commitment, she often described her career not simply as a job but as a “mission,” emphasizing both her personal and professional passion for making a difference in human health.

🧪 Contributions and Research Focus

Specializing in clinical trials, Dr. Weimer has coordinated and participated in numerous groundbreaking studies in HIV and Hepatitis C (HCV). Since the early 1990s, she has collaborated closely with renowned figures such as Prof. Giovanni Rossi, Prof. Stefano Vella, and Prof. Gianni Rezza, contributing to some of the most pivotal HIV antiretroviral therapy trials in history. Her research efforts extended to co-leading and organizing both national and international multicenter clinical trials. Notably, she has been at the forefront of the PITER study, a major nationwide cohort that follows 25,000 patients undergoing HCV treatment—one of the most comprehensive initiatives in Italy in the fight against hepatitis.

🌍 Global Collaborations and Humanitarian Engagement

Her impact extends beyond Italy, thanks to her active involvement with the U.S.-based American Clinical Trials Group on HIV studies. These collaborations have enhanced international understanding and treatment of HIV/AIDS. In addition to her clinical and research commitments, Dr. Weimer also devoted herself to frontline service during the COVID-19 pandemic. Volunteering both with the Civil Protection unit and at Bambino Gesù Children’s Hospital, she demonstrated profound humanitarian values. Her presence during a critical time underscored her belief in serving communities not just from behind a lab desk but also on the ground, directly supporting patients and health systems under strain.

🏅 Accolades and Recognition

Dr. Weimer’s work has been acknowledged at both national and international levels. One of the most prominent recognitions she received was the 1st Prize at the International Congress on Hepatitis C held in Seville in November 2019, a testament to her excellence and influence in the field of infectious disease research. Her achievements are not only measured in accolades but also in the tangible difference her work has made in advancing therapy options and clinical management of chronic viral diseases. Her rise within the ISS and the trust placed in her leadership of major research projects further affirm her standing within the scientific community.

💡 Impact and Influence

Over the course of her extensive career, Dr. Weimer has significantly shaped clinical research strategies in Italy, especially regarding chronic viral infections. Her coordination of thousands of patient cases within structured clinical trials has informed policy decisions and improved treatment protocols nationwide. Her presence at the ISS has also influenced future generations of researchers and clinicians, many of whom benefited from her mentorship, leadership, and example of scientific integrity. Through her rigorous methods and patient-focused approach, she has played a key role in Italy’s standing as a leader in global health research, especially in relation to HIV and HCV.

🔬 Legacy and Future Contributions

Looking forward, Dr. Weimer’s contributions will continue to echo through the fields of virology and clinical medicine. Her involvement in the PITER cohort and other studies has laid down essential groundwork for long-term epidemiological surveillance and patient care strategies. With her appointment as First Researcher, she enters a new chapter of leadership, likely to drive more innovative, patient-centered research initiatives in global health. Her legacy lies not only in her publications or awards but also in the thousands of lives improved by the treatments she helped to test, refine, and implement. The combination of scientific rigor and heartfelt service defines her enduring contribution to modern medicine.

Publication

  • Outcome of sustained virological responders with histologically advanced chronic hepatitis C – TR Morgan, MG Ghany, HY Kim, KK Snow, ML Shiffman, JL De Santo, … – 2010

 

  • Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5‐year follow‐up of 150 patients – SL George, BR Bacon, EM Brunt, KL Mihindukulasuriya, J Hoffmann, … – 2009

 

  • Safety and efficacy of simeprevir/sofosbuvir in hepatitis C–infected patients with compensated and decompensated cirrhosis – V Saxena, L Nyberg, M Pauly, A Dasgupta, A Nyberg, B Piasecki, … – 2015

 

  • Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy – D Persaud, SC Ray, J Kajdas, A Ahonkhai, GK Siberry, K Ferguson, … – 2007

 

  • Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real‐world cohort study – EB Tapper, BR Bacon, MP Curry, DT Dieterich, SL Flamm, LE Guest, … – 2016

 

  • Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with< 50 copies/ml HIV-1 RNA – S Baroncelli, CM Galluzzo, MF Pirillo, MG Mancini, LE Weimer, … – 2009

 

  • Predictors of failure with high-flow nasal oxygen therapy in COVID-19 patients with acute respiratory failure: a multicenter observational study – R Mellado-Artigas, LE Mujica, ML Ruiz, BL Ferreyro, F Angriman, E Arruti, … – 2021

 

  • A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients – M Floridia, R Bucciardini, D Ricciardulli, V Fragola, MF Pirillo, LE Weimer, … – 1999

 

  • Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohort – LA Kondili, F Romano, FR Rolli, M Ruggeri, S Rosato, MR Brunetto, … – 2017

 

  • Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER network – LA Kondili, GB Gaeta, D Ieluzzi, AL Zignego, M Monti, A Gori, A Soria, … – 2017

 

🏁 Conclusion

Dr. Weimer stands as a distinguished figure in the field of global health research, with deep expertise in clinical trials and infectious diseases. Her legacy is marked by landmark contributions to HIV and HCV treatment protocols, influential collaborations, and compassionate public service. Her ongoing work continues to shape public health policy and medical research in Italy and beyond. As she advances in her leadership role at the ISS, her experience, insight, and dedication will remain vital to future innovations in clinical research and global health.

Rosario Osta | Molecular and Cellular Neuroscience | Best Researcher Award

Posted on by Neuroscientists

Prof.Dr. Rosario Osta | Molecular and Cellular Neuroscience | Best Researcher Award

Prof. Dr. Rosario Osta, CIBERNED-Fundación Instituto de Investigación Sanitaria de Aragón-Universidad de Zaragoza,  Spain.

Prof. Rosario Osta Pinzolas is a distinguished geneticist and full professor at the University of Zaragoza, Spain. Her academic roots in veterinary sciences and a Ph.D. in Genetics laid the foundation for a prolific career in biomedical research, particularly in the fields of neuroscience and genetic disorders. With leadership roles in multiple high-profile research consortia such as CIBERNED, TRICALS, and ENCALS, she has established herself as a central figure in neurodegenerative disease research. Her scholarly output includes over 100 indexed publications, multiple national and international research projects, and an h-index exceeding 45.

Profile

Orcid 

Scopus

 

🎓 Early Academic Pursuits

Rosario Osta Pinzolas began her academic journey with a solid foundation in veterinary sciences, graduating as Licenciada en Veterinaria from the University of Zaragoza in 1989. Her academic inclinations quickly shifted toward molecular genetics, leading her to complete a Ph.D. in Genetics at the same university in 1994. Her early studies were driven by a deep curiosity about the mechanisms of heredity and gene expression, setting the tone for a lifelong commitment to biomedical research. These formative years cultivated her scientific rigor and sowed the seeds for a career that would eventually bridge basic science and translational medicine.

🧬 Professional Endeavors in Genetics and Biomedicine

Prof. Osta currently holds the esteemed title of Catedrática (Full Professor) in the Department of Anatomy, Embryology, and Genetics at the Faculty of Veterinary Medicine, University of Zaragoza. Since 2018, she has led her department with a focus on integrative biomedical sciences. She is the principal investigator of the LAGENBIO group recognized by both the Aragon Health Research Institute and the Government of Aragon. Under her leadership, the group has developed two major subprograms: TERAGEN and REGENERAGEN. As coordinator of the “Neuroscience and Mental Health Program” at IISA, she has spearheaded numerous efforts to understand and address neurological diseases through genetic approaches.

🧠 Contributions and Research Focus in Neuroscience

A prominent figure in neuroscience, Prof. Osta’s research lies at the intersection of genetics and neurodegeneration. She is currently the principal investigator of the only Aragon-based group within CIBERNED (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas), reflecting her national influence. Her team represents Zaragoza in prominent European consortia such as TRICALS and ENCALS, both focused on amyotrophic lateral sclerosis (ALS) and other motor neuron diseases. Through more than 100 indexed publications, predominantly in top-tier journals, her work delves into the molecular underpinnings of neurological disorders and explores regenerative medicine strategies, thereby contributing to innovative therapeutic avenues.

🧪 Accolades and Recognition in Scientific Excellence

Prof. Osta’s academic and research career has been punctuated by consistent recognition. She has completed five research productivity periods and one technology transfer period, acknowledged by CNEAI — a mark of sustained scientific impact. She has led over 74 research projects and contributed to more than 100 collaboration contracts, earning her four competitive research awards from respected institutions including CORIS, AREA, IIS, and SEBBM. Her contributions have been lauded not only for scientific quality but also for practical relevance in biomedical advancements.

🚀 Innovation and Impact in Translational Research

An ardent advocate for science with societal impact, Prof. Osta has significantly contributed to technology transfer. She holds nine patents, five of which have been licensed to industry partners. Her collaborations with companies have led to meaningful translational outputs, emphasizing her role in bridging the gap between academic research and real-world solutions. As former Director of the Technology Transfer and Innovation Secretariat at the University of Zaragoza for nearly a decade, she played a crucial role in institutional innovation strategies. Her involvement in joint university-company chairs and her role in the UZ Technology-Based Business Creation Committee for over 12 years further underscore her influence on academic entrepreneurship.

📚 Mentorship and Educational Leadership

Beyond the lab, Prof. Osta has left a profound mark as an educator and mentor. Since 2013, she has coordinated the Interuniversity Doctoral Program in Biomedical and Biotechnological Sciences, a joint initiative between the Universities of Zaragoza and La Rioja. Her mentorship includes the supervision of 13 Ph.D. theses — 9 of which earned international distinction and 6 received extraordinary doctoral awards. Her influence extends to guiding numerous undergraduate and master’s theses, fostering a new generation of scientists with a deep commitment to research excellence and innovation.

🌍 Legacy and Future Contributions

Prof. Rosario Osta’s legacy is defined by her ability to integrate scientific discovery, mentorship, and innovation. As a member of the Scientific Committee of the Luzón Foundation, her vision reaches beyond academia into public health advocacy and strategic research planning. With nearly 19,000 citations on Google Scholar and an h-index of 45, her work continues to inspire and inform global research communities. Her continued leadership in collaborative European projects ensures her contributions will shape the future of neuroscience, genetics, and translational medicine for years to come.

Publication

Title: Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1G93A amyotrophic lateral sclerosis (ALS) mice
Authors: L. Moreno-Martinez, N. Gaja-Capdevila, L. Mosqueira-Martín, R. Osta, F.J. Gil-Bea
Year: 2025

Title: Identifying Hub Genes and miRNAs Associated with Alzheimer’s Disease: A Bioinformatics Pathway to Novel Therapeutic Strategies
Authors: E. Gascón, A.C. Calvo, N. Molina, P. Zaragoza, R. Osta
Year: 2024

Title: Comparative Blood Profiling Based on ATR-FTIR Spectroscopy and Chemometrics for Differential Diagnosis of Patients with Amyotrophic Lateral Sclerosis—Pilot Study
Authors: K. Tkachenko, J.M. González Sáiz, A.C. Calvo, R. Osta, C. Pizarro Millán
Year: 2024

Title: Sex differences on constitutive long non-coding RNA expression: Modulatory effect of estradiol and testosterone in muscle cells
Authors: T. López-Royo, L. Moreno-Martinez, L. Moreno-García, R. Manzano, R. Osta
Year: 2024

Title: Differentially expressed lncRNAs in SOD1 G93A mice skeletal muscle: H19, Myhas and Neat1 as potential biomarkers in amyotrophic lateral sclerosis
Authors: T. López-Royo, L. Moreno-Martinez, P. Zaragoza, R. Manzano, R. Osta
Year: 2024

Title: Proteomic profiling of human plasma extracellular vesicles identifies PF4 and C1R as novel biomarker in sarcopenia
Authors: P. Aparicio, D. Navarrete-Villanueva, A. Gómez-Cabello, R. Osta, R. Manzano
Year: 2024

Title: Sporadic Amyotrophic Lateral Sclerosis Skeletal Muscle Transcriptome Analysis: A Comprehensive Examination of Differentially Expressed Genes
Authors: E. Gascón, P. Zaragoza, A.C. Calvo, R. Osta
Year: 2024

Title: Intermediate Repeat Expansion in the ATXN2 Gene as a Risk Factor in the ALS and FTD Spanish Population
Authors: D. Borrego-Hernández, J.F. Vázquez-Costa, R. Domínguez Rubio, M. Povedano, A. García-Redondo
Year: 2024

Title: New Insights into Endogenous Retrovirus-K Transcripts in Amyotrophic Lateral Sclerosis
Authors: L. Moreno-Martinez, S. Macías-Redondo, M.H.P. Strunk, R. Osta, J. Schoorlemmer
Year: 2024

Title: Analysis of Plasma-Derived Exosomal MicroRNAs as Potential Biomarkers for Canine Idiopathic Epilepsy
Authors: M. García-Gracia, L. Moreno-Martinez, A. Hernaiz, S. García-Belenguer, I. Martín-Burriel
Year: 2024

🏆 Conclusion

Based on her outstanding research contributions, innovation in translational science, mentorship record, and leadership within national and European research programs, Prof. Rosario Osta Pinzolas is an exceptionally strong candidate for the Best Researcher Award. Her profile reflects not only academic excellence but also societal impact and visionary leadership. While there is room for enhanced global outreach, her sustained achievements and contributions make her highly deserving of this prestigious recognition.